[1] 农村立,郭堑,韦秋芳,等.DPMAS序贯血浆置换治疗乙型肝炎病毒相关慢加急性肝衰竭的短期疗效.重庆医学,2019,48:608-611. [2] 左同坤,郑以山,汤庆,等.双重血浆分子吸附系统联合血浆置换用于慢加急性肝衰竭的价值.湖南师范大学学报(医学版),2020,17:79-83. [3] 赵紫烟,安雪青,史丽,等.血清前白蛋白/总胆红素比值对肝衰竭患者预后的预测价值.中国现代医学杂志,2017,27:75-78. [4] 皇甫彤,王伟红.胆碱酯酶和甲胎蛋白评估亚急性肝衰竭患者预后的价值.医学临床研究,2019,36:1232-1234. [5] 中华医学会感染病学分会肝衰竭与人工肝学组,中华医学会肝病学分会重型肝病与人工肝学组.肝衰竭诊治指南(2018年版).中华临床感染病杂志,2018,11:E001-E001. [6] 肝性脑病诊断治疗专家委员会.肝性脑病诊断治疗专家共识.中华实验和临床感染病杂志(电子版),2009,3:51-56. [7] 李永超,任红军,刘磊,等.双重血浆吸附联合血浆置换治疗慢加急性乙型肝炎 肝衰竭患者临床疗效研究.实用肝脏病杂志,2020,23:236-239. [8] Arbab K,Majid H,Jafri L,et al.Assessing Nutritional Status Of Critically Ill Patients Using Serum Prealbumin Levels.J Ayub Med Coll Abbottabad,2019,31:178-181. [9] Huang L,Li J,Yan JJ,et al.Prealbumin is predictive for postoperative liver insufficiency in patients undergoing liver resection.World J Gastroenterol,2012,18:7021-7025. [10] 张文佳,赵丽娟,吴基洲.MELD、AARC、COSSH 评分系统对乙型肝炎相关慢加急性肝衰竭90 天预后的评估价值.临床肝胆病杂志,2020,36:813-817. [11] Tong JJ,Zhao W,Mu XY,et al.Predictive value of the Chinese group on the study of severe hepatitis B-acute-on-chronic liver failure score in the short-term prognosis of patients with hepatitis B virus-related acute-on-chronic liver failure.Chin Med J (Engl),2019,132:1541-1549. [12] 贾玲,娄宪芝,那妍.血清前白蛋白总胆红素比值水平评估 慢性乙型肝炎恩曲他滨治疗耐药性的价值.2020,15:59-62. [13] 李艳艳,徐龙.血清前白蛋白与总胆红素比值、ALBI评分、MELD评分与慢加急性肝衰竭患者预后的关系.中西医结合肝病杂志,2020,30:417-419. [14] 程序,周英发,贾萌萌,等.血清前白蛋白总胆红素比值在肝脏TACE术患者预后评估中的应用价值.中国现代医药杂志,2020,22:10-14. [15] Wang X,Shen C,Yang J,et al.Alpha-Fetoprotein as a Predictive Marker for Patients with Hepatitis B-Related Acute-on-Chronic Liver Failure.Can J Gastroenterol Hepatol,2018,2018:1232785. [16] Kakisaka K,Kataoka K,Onodera M,et al.Alpha-fetoprotein: A biomarker for the recruitment of progenitor cells in the liver in patients with acute liver injury or failure.Hepatol Res,2015,45:E12-20. [17] 秦森,汤善宏,王显红,等.血清甲胎蛋白在人工肝治疗乙型肝炎相关慢加急性肝衰竭预后评估中的价值.中华肝脏病杂志,2020,28:69-72. |